Renal denervation (RDN) has been shown to be effective and safe, resulting in better control of blood pressure and an improvement in left ventricular hypertrophy in chronic kidney disease (CKD) patients. Ventricular arrhythmias and sudden cardiac death are common causes of death in CKD patients, but previous studies pay almost no attention to the effects of RDN on the risk of ventricular fibrillation associated with CKD. r What is the main finding and its importance?
Introduction
Chronic kidney disease (CKD) is a chronic, progressive and multifactorial disorder, with an increased risk of cardiovascular morbidity and mortality (Gansevoort et al. 2013; Di Lullo et al. 2016) . Sudden cardiac death (SCD)-related mortality is increased 14-fold in dialysis patients when compared with subjects who have normal kidney function (Di Lullo et al. 2016) . Even mild changes in renal function also increase the risk of SCD, especially in older populations. It is well recognized that sympathetic nervous system activation plays a crucial role in disease development, progression and adverse outcomes in CKD patients (Ewen et al. 2013; Johns, 2014) . Even in the early stage of CKD, sympathetic overactivity is already present and increases in parallel with the progression of hypertension and impairment of kidney function.
In recent years, renal denervation (RDN) has emerged as a new approach to decrease sympathetic activity Schlaich et al. 2009; Linz et al. 2015) . Several clinical studies have shown that RDN exerts promising therapeutic effects on left ventricular (LV) hypertrophy (LVH) and blood pressure control in CKD patients with resistant hypertension (Kiuchi et al. 2013 (Kiuchi et al. , 2016 Hering et al. 2017) . However, previous studies have paid almost no attention to the effects of RDN on CKD-associated ventricular arrhythmias and SCD. We hypothesized that RDN might provide protection against CKD-related ventricular fibrillation (VF) through multiple mechanisms, including improvement of LVH, sympathetic activation and inflammation. In the present study, we created a canine CKD model by subtotal nephrectomy and measured the parameters of renal function, blood pressure, echocardiography, ECG, noradrenaline (NA), inflammation and ventricular fibrillation threshold (VFT) to test the hypotheses.
Methods

Ethical approval
Animal studies were reviewed and approved by the Institutional Animal Care and Use Committee of Wuhan University of Science and Technology (permit no. 20160217) . All procedures conformed to the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication, revised 2011) . All experiments comply with the principles and regulations, as described by Grundy (2015) . All efforts were made to minimize the number of animals used and their suffering. At the end of study, all animals were not allowed to recover, and were killed with an overdose of sodium pentobarbital (150 mg kg −1 , I.V., Merck, Darmstadt, Germany).
Surgical procedure
Twenty-one adult male dogs weighing 12-14 kg were provided by the animal centre in the medical college of Wuhan University of Science and Technology. The dogs were anaesthetized with 30 mg kg −1 (I.V.) sodium pentobarbital via the cephalic vein, and general anaesthesia was maintained with an additional dose of 2 mg kg −1 (I.V.) at the end of each hour. The depth of anaesthesia was monitored throughout the experiment by checking heart rate, breathing rate, the corneal reflex and the toe-pinch response. The dogs were intubated and ventilated with a positive pressure respirator. In 16 dogs, bilateral flank incisions were performed to expose the left and right kidneys. Several dorsal and ventral branches of the left and right renal arteries were ligated to achieve a target of 50-60% infarction of both the kidneys (established by visual verification of topical cyanosis; Kingma et al. 2014) . In eight of 16 CKD dogs, both kidneys were surgically denervated by cutting all visible nerves of the adventitia of the renal arteries (CKD + RDN group), and then the arteries were moistened with a 20% phenol-ethanol solution for 10-15 min. Renal denervation was considered successful when electrical stimulation of each renal artery did not produce any changes of blood pressure. Sham denervation was performed in the remaining eight CKD dogs (CKD group). Another five sham-operated dogs underwent the same anaesthetic and surgical protocols as the CKD dogs, but the kidneys were only gently manipulated before closure of the incisions (CTR group). The incisions were closed in layers. Analgesia was provided with butorphanol (0.2 mg kg −1 , I.M., twice daily, Hengrui Medicine Co., LTD, Jiangsu, China) for 3 days.
Animals were housed in a colony room with controlled temperature (22-24°C) and a 12 h-12 h dark-light cycle (light on at 07.00 h), with food and water provided ad libitum. After 6 weeks follow-up, all dogs were again anaesthetized (same procedure as described in the previous paragraph) for measurements and for the second operation to determine the VFT (as described below, in the subsection 'Ventricular fibrillation threshold measurements'). The design and time line of the experiments are shown in Fig. 1 .
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Serum measurements
At baseline and at the 6th week of follow-up, before anaesthesia, blood samples were collected from the cephalic vein into an ice-chilled tube, and immediately centrifuged at 2310g for 10 min at 4°C, and then stored at −80°C until further assay. Concentrations of blood urea nitrogen, creatinine, haemoglobin, NA, C-reactive protein (CRP) and interleukin-6 (IL-6) were examined using enzyme-linked immunosorbent assay kits (Wuhan Beinglay Biotech Co., Ltd, Hubei, China).
Echocardiography measurements
At baseline and at 6th week of follow-up, transthoracic Doppler echocardiography was performed under general anaesthesia, before the operations, with a Vivid 7 system (GE Vingmed Ultrasound, Horten, Norway). Images of long-axis, short-axis and apical four-chamber views were obtained. The end-diastolic left ventricular internal dimension (LVIDd), the left ventricular end-diastolic posterior wall thickness (PWTd) and the end-diastolic interventricular septum thickness (IVSTd) were measured. The left ventricular (LV) mass was calculated from LV linear dimensions using the Devereux formula (Devereux et al. 1986 ). All echocardiograms were measured blind to the investigator in triplicate by the same sonographer, and the averages were taken for analysis.
Electrocardiographic measurements
At baseline and after 6 weeks follow-up, a 12-lead ECG was recorded using adhesive leads, under general anaesthesia before the operations. The QT interval was measured from the beginning of the QRS complex to the end of the T wave, and corrected for heart rate using the Bazett formula, as QT/(RR) 0.5 , where RR is the R-R interval. The QT dispersion (QTd) was defined as the difference between the maximal and minimal QT intervals of the 12 leads. The Tpeak to Tend (Tp-e) interval was defined as the interval from the peak to the end of T wave, and was corrected for heart rate using the Bazett formula, as Tp-e/(RR) 0.5 . The ratio of Tp-e/QT was then calculated from these values. The ECG parameters were measured blind to the investigator and by two experts and by averaging three consecutive beats.
Ventricular fibrillation threshold measurements
At the end of the study, a right thoracotomy was performed under anaesthesia at the fifth intercostal space, followed by a pericardiotomy and placement of one electrode catheter at the right ventricular apex. The VFT was also measured blind to the investigator and with right ventricular pacing using a train of 30 stimuli (30 ms interval), which was performed at the end of a 20 beat drive train at 300 ms, to ensure that VFT was measured at the same heart rate (Huang et al. 2015) . The VFT was determined by progressively increasing the pacing voltage in 2 V steps, with a 20 s rest period before the next pacing train if no ventricular fibrillation was induced. The VFT was defined as the minimal voltage required to induce sustained VF. Once VF occurred, no intervention was adopted to terminate VF. All dogs in which VF occurred were killed with an overdose of sodium pentobarbital (150 mg kg −1 , I.V.). 
Blood, ECG, UCG
Statistical analysis
Continuous variables are shown as means ± SD. The differences between baseline and follow-up measurements were assessed by Student's paired t test. Differences between groups (except for VFT) were evaluated with repeated-measures two-way ANOVA followed by Bonferroni test if ANOVA was significant. One-way ANOVA followed by Bonferroni test was used to compare the VFT means between groups. The P values were two-sided and considered significant when <0.05. Statistical analyses were carried out using the SPSS version 18.0 software package (SPSS Inc., Chicago, IL, USA).
Results
After 6 weeks follow-up, high-frequency stimulation of both renal arteries did not induce any changes in blood pressure in the CKD + RDN group, indicating that renal nerve reinnervation may not occur at 6 weeks after RDN in this study.
Assessment of CKD
The data for body weight, serum creatinine, blood urea nitrogen and haemoglobin are summarized in Table 1 . The baseline values of these indicators were not significantly different among the three groups. After 6 weeks follow-up, the body weight and haemoglobin were significantly decreased, whereas serum creatinine and blood urea nitrogen were significantly increased in both the CKD group and the CKD + RDN group when compared with the CTR group, indicating that the canine CKD model was successfully induced by subtotal nephrectomy.
Renal denervation attenuates blood pressure elevation Figure 2 shows the changes in blood pressure in each group. No significant differences were shown in the baseline blood pressure among the three groups. As a result of CKD, systolic blood pressure, diastolic blood pressure and mean arterial pressure were all significantly increased in the CKD and CKD + RDN groups when compared with the CTR group. The systolic and diastolic blood pressures and mean arterial pressure were all significantly lower in the CKD + RDN group compared with the CKD group, indicating that RDN attenuated the blood pressure elevation induced by CKD.
Renal denervation attenuates LVH
As shown in and diastolic blood pressure (DBP; C) in each group. In this and the following figures, the horizontal black line and the limits depict mean and SD, respectively. a P < 0.05 versus baseline; b P < 0.05 versus CTR group; and c P < 0.05 versus CKD group (a: using Student's paired t test; b and c: using repeated-measures two-way ANOVA followed by Bonferroni test).
X. Tang and others Body weight (kg) 11.0 ± 0.4 11.4 ± 0.5 11.2 ± 0.2 9.6 ± 0.3 * † 10.9 ± 0.3 9.8 ± 0.3 * † Serum creatinine (μM) 6 4± 14 70 ± 16 60 ± 12 130 ± 22 * † 62 ± 11 122 ± 25 * † Blood urea nitrogen (mM) 4 . 2± 1.0 4.5 ± 1.2 4.4 ± 0.8 9.7 ± 1.9 * † 4.5 ± 1.2 9.1 ± 2.0 * † Haemoglobin (g dl −1 ) 11.5 ± 1.6 11.3 ± 0.9 11.2 ± 1.2 8.1 ± 1.1 * † 11.3 ± 0.9 8.4 ± 1.2 * † Abbreviations: 6W, after 6 weeks follow-up; BS, baseline; CKD, chronic kidney disease; CTR, control; and RDN, renal denervation. * P < 0.05 versus BS (using Student's paired t test); † P < 0.05 versus CTR group (using repeated-measures two-way ANOVA followed by Bonferroni test).
among the three groups. However, 6 weeks after CKD, the LV mass (92.7 ± 25.9 versus 56.7 ± 10.9 g, P < 0.05), LVIDd (30.1 ± 1.7 versus 26.8 ± 0.8 mm, P < 0.05), PWTd (10.6 ± 1.6 versus 8.6 ± 1.2 mm, P < 0.05) and LVSTd (10.5 ± 1.6 versus 8.6 ± 1.1 mm, P < 0.05) were all significantly increased in the CKD group when compared with the CTR group. However, CKD-induced changes in LV mass (61.4 ± 11.4 versus 92.7 ± 25.9 g, P < 0.05), LVIDd (28.1 ± 2.1 versus 30.1 ± 1.7 mm, P < 0.05), PWTd (8.8 ± 0.7 versus 10.6 ± 1.6 mm, P < 0.05) and LVSTd (8.6 ± 0.8 versus 10.5 ± 1.6, P < 0.05) were significantly attenuated by RDN. The LVEF was not significantly changed after 6 weeks follow-up in all three groups. Figure 4A shows representative ECG traces in each group before and 6 weeks after operations. The values of ECG parameters at baseline showed no significant difference among the three groups. After 6 weeks follow-up, the dogs in the CKD group exhibited shorter RR interval, longer QT interval, corrected QT (QTc) interval, Tp-e interval , the left ventricular end-diastolic posterior wall thickness (PWTd; C), the end-diastolic interventricular septum thickness (IVSTd; D) and the left ventricular ejection fraction (LVEF; E) in each group. a P < 0.05 versus baseline; b P < 0.05 versus CTR group; and c P < 0.05 versus CKD group (a: using Student's paired t test; b and c: using repeated-measures two-way ANOVA followed by Bonferroni test).
Renal denervation attenuates the changes of ECG parameters
and corrected Tp-e (cTp-e) interval, and larger QTd and Tp-e/QT when compared with the CTR group. However, CKD combined with RDN significantly attenuated the CKD-induced ECG changes ( Fig. 4B-H ).
Renal denervation attenuates the changes of VFT
The VFT was measured at the end of study (Fig. 5) . When compared with the CTR group, the VFT was significantly lower in the CKD group (10.1 ± 4.2 versus 20.1 ± 5.2 V, P < 0.05) and the CKD + RDN group (16.2 ± 4.0 versus 20.1 ± 5.2 V, P < 0.05). However, the VFT was even lower in the CKD group when compared with the CKD + RDN group (10.1 ± 4.2 versus 16.2 ± 4.0 V, P < 0.05).
Renal denervation attenuates the changes of serum NA, CRP and IL-6
As shown in Fig. 6 , the serum concentrations of NA, CRP and IL-6 at baseline were not significantly different among the three groups. After 6 weeks follow-up, serum NA, CRP and IL-6 concentrations were markedly increased in the CKD and CKD + RDN groups. However, when compared with the CKD group, RDN significantly decreased the serum NA, CRP and IL-6.
Discussion
The main findings of this study were as follows: (i) subtotal nephrectomy-induced CKD was associated with an increased risk of ventricular fibrillation (longer , QT dispersion (QTd; E), Tp-e interval (F), corrected Tp-e (cTp-e) interval (G) and Tp-e/QT ratio (H). a P < 0.05 versus baseline; b P < 0.05 versus CTR group; and c P < 0.05 versus CKD group (a: using Student's paired t test; b and c: using repeated-measures two-way ANOVA followed by Bonferroni test).
QT interval, QTc interval, Tp-e interval and cTp-e interval, larger QTd and Tp-e/QT, and lower VFT) which, however, was attenuated by RDN; and (ii) improvement of LVH, sympathetic activation and inflammation may be responsible for the protective effects of RDN against ventricular fibrillation. The findings suggest that RDN might be a promising approach for prevention of malignant ventricular arrhythmias and SCD in CKD patients.
Chronic kidney disease-related ventricular fibrillation and SCD and the therapeutic role of RDN
It is well accepted that cardiovascular complications are the leading causes of deaths in patients with CKD (Gansevoort et al. 2013) . Ventricular tachyarrhythmias are common in CKD patients, with a progressive increase in the incidence of SCD with loss of renal function (Green et al. 2011) . Data from the US Renal Data System Annual Data Report suggested that SCD accounts for ß25% of all-cause mortality. In the present study, after 6 weeks follow-up, subtotal nephrectomy induced significant increases in serum creatinine and blood urea nitrogen, and decreases in body weight and serum haemoglobin, in both the CKD group and the CKD + RDN group, indicating that the CKD model was successfully created. To evaluate the risk of ventricular fibrillation, we measured the ECG parameters and VFT. It has been shown that prolonged repolarization or increased dispersion of repolarization might predispose patients to malignant ventricular arrhythmias (Watanabe et al. 2004) . Previously, QT and QTc intervals and QT dispersion have been used to evaluate myocardial repolarization, and thus estimate the arrhythmogenic risk to the heart (Topilski et al. 2007 ). Besides, Tp-e and cTp-e intervals and the Tp-e/QT ratio have been widely used to evaluate the risk of malignant ventricular arrhythmias (Castro Hevia et al. 2006; Alizade et al. 2017) . Dobre et al. (2012) examined the ECG parameters in 1192 participants with CKD, and their results showed that 68.5% of these patients had major (38.8%) or minor (29.7%) ECG abnormalities, including prolongation of the QT and QTc intervals, which are independent risk markers for cardiovascular death. In the present study, we also found that the dogs in the CKD group exhibited prolonged QT, QTc, Tp-e and cTp-e intervals and increased QTd and Tp-e/QT ratio, suggesting an increased risk of VF in CKD dogs. In addition, the VFT was significantly decreased in the CKD group when compared with the CTR group, further indicating an increased susceptibility of the heart to VF in the CKD dogs.
Renal denervation for the treatment of resistant hypertension has been met with great enthusiasm by cardiologists during recent years Linz et al. 2017) . Although the Symplicity HTN-3 trial failed to demonstrate a beneficial effect of RDN in patients with resistant hypertension (Bhatt et al. 2014) , several factors, such as increased placebo effect, inadequate denervation or an inability to test for successful denervation, might have contributed to the negative results. In addition to resistant hypertension, RDN might have great potential in the treatment of other diseases associated with excessive sympathetic activation (Bohm et al. 2014) . Recently, several clinical studies have suggested that RDN also exerts beneficial effects in CKD patients. Kiuchi et al. (2013) performed RDN in 24 CKD patients. After 6 months follow-up, the results showed that RDN was effective and safe, resulting in a better control of blood pressure, a short-term improvement in renal function, and reduced albuminuria. In a study with a longer follow-up period (24 months), Hering et al. (2017) also showed that RDN could halt the progression of CKD and improve blood pressure control in CKD patients. However, in these studies almost no attention has been paid to the effects of RDN on CKD-associated ventricular fibrillation and SCD. In normal healthy dogs, Huang et al. (2014) showed that RDN significantly increased the ventricular electrophysiological stability. Basic and clinical studies have also shown that RDN can decrease ventricular tachyarrhythmias in different clinical settings Remo et al. 2014; Ukena et al. 2016) . In the present study, we showed that RDN significantly attenuated CKD-induced VFT reduction and ECG changes, including QT, QTc, Tp-e and cTp-e interval prolongation and QTd and Tp-e/QT ratio elevations. The present study indicates that RDN is capable of protecting against VF in this CKD model.
Possible mechanisms underlying the protective effects of RDN against VF
There is a progressive increase in the prevalence of LVH, and LV mass increases when the estimated glomerular filtration rate decreases (Cerasola et al. 2010) . At the start of dialysis, LVH is present in >75% of patients with advanced CKD (Foley et al. 2010 ) and has been linked to an increased risk of sustained ventricular arrhythmias and predisposition to SCD (Haider et al. 1998) . The echocardiogram results in the present study showed that LV mass, LVIDd, PWTd and LVSTd were all significantly increased in the CKD group when compared with the CTR group, suggesting a progression of LVH, which might contribute to the increased risk of VF. However, CKD + RDN significantly decreased LV mass, LVIDd, PWTd and LVSTd when compared with the CKD group, indicating that RDN attenuated the progression of LVH in CKD dogs, consistent with a recent clinical study by Kiuchi et al. (2016) , who showed that RDN was effectively and safely able to improve the LVH in CKD refractory hypertensive patients. Therefore, improvement of CKD-induced LVH by RDN might contribute to its anti-VF action.
Increased sympathetic activation is found in the initial clinical stages of CKD and greatly contributes to the increased cardiovascular risk (Ewen et al. 2013) . Afferent signals from renal sensory nerves could activate the sympathetic nervous system (Hering et al. 2013) , resulting in NA release, which is involved in the pathogenesis of LVH and creates a substrate for SCD. In the present study, we found that blood pressure and serum NA were significantly increased in the CKD group, indicating a significant increase in sympathetic activity. Previous studies have also found that CKD patients have a withdrawal in parasympathetic modulation of the heart rate in conjunction with an increase in sympathetic input to the sinoatrial node (Chan, 2008) . In the present study, the R-R interval was markedly decreased in CKD dogs, consistent with previous studies (Liang et al. 2014) . However, CKD + RDN significantly attenuated the elevations of blood pressure and NA and increased the R-R interval when compared with the CKD group, indicating that inhibition of sympathetic activation might be another mechanism underlying the protective effects of RDN against VF.
In addition to LVH and sympathetic activation, inflammation also has been found to be associated with SCD independently of traditional cardiovascular risk factors (Di Lullo et al. 2016) . Serum pro-inflammatory cytokine concentrations increase with a decline in renal function. Both CRP and IL-6 have been associated with ventricular arrhythmias (Parekh et al. 2008) . The inflammatory process could promote ventricular remodelling, affecting ventricular conduction, causing a delay in repolarization and thus leading to ventricular arrhythmias and SCD (Parekh et al. 2008) . In the present study, CKD dogs had higher serum concentrations of Figure 6 . Serum concentrations of noradrenaline (NA; A), C-reactive protein (CRP; B) and interleukin-6 (IL-6; C) a P < 0.05 versus baseline; b P < 0.05 versus CTR group; and c P < 0.05 versus CKD group (a: using Student's paired t test; b and c: using repeated-measures two-way ANOVA followed by Bonferroni test).
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CRP and IL-6, which were attenuated by RDN. Therefore, suppression of the inflammatory response by RDN might also contribute to its anti-VF action.
Study limitations
There are several limitations in this study. First, the pathophysiological process and severity of renal impairment in our model are not completely in accord with clinical CKD situations. Further, clinical studies might be designed to evaluate whether catheter-based RDN could attenuate the ECG parameters and prevent ventricular arrhythmias and SCD in CKD patients. Second, this study has a small sample size, which might reduce power to detect small but clinically significant effects. Third, we performed combined surgical and chemical RDN, which might be more complete compared with the catheter-based RDN. However, it has been shown that NA reduction in the kidney was similar between surgical RDN and catheter-based RDN . Fourth, there were no occurrences of spontaneous VF in this study, because the dogs were followed up for only 6 weeks. Besides, we measured only the VFT but did not determine other invasive ventricular electrophysiological parameters, such as ventricular effective refractory period and action potential duration. However, the non-invasive ECG parameters were analysed in the present study to reflect the risk of ventricular arrhythmias. Fifth, further studies might be performed to assess the additional values of RDN in combination with angiotensin-converting enzyme inhibitors, β-adrenoceptor blockers, or both, in the management of CKD patients.
Conclusions
The present study demonstrated that RDN could decrease susceptibility of the heart to VF in a canine model of CKD induced by subtotal nephrectomy. Improvement of LVH, sympathetic activation and inflammation by RDN may be responsible for its beneficial effects. Renal denervation may be a promising approach for prevention of malignant ventricular arrhythmias and SCD in CKD patients.
